ia臨床概念的進(jìn)展黃一寧-資料下載頁(yè)
2025-05-25 22:48本頁(yè)面
【正文】 ROSPER Pravastatin (40mg) Stroke+TIA NS PROSPER Pravastatin(40mg) TIA 25% P= ASCOT Atorvastatin(10mg) Stroke 27% P= ACEI Plaque with stable fibrous cap formation : mod. nach Ross R, N Engl J Med 340 (1999) amp。 Falk et al., Circulation 92 (1995) Fibrous cap formation Macrophage accumulation Formation of necrotic core Pathophysiology of Atherosclerosis (III) Vessel wall Coronary plaque with lipid core PlaqueACE and Atherosclerosis Major role in atherosclerotic pathways: Endothelial dysfunction Thrombosis Inflammation Vasoconstriction Vascular lesions Remodeling Plaque rupture PlaqueACE Local Mediators VCAM ICAM Cytokines Endothelin PAI1 Growth factors Proteolysis Ang II Bradykinin NO Clinical Sequelae Ang II adapt. from Pepine C, Can J Cardiol 14。 suppl D (1998) ACEIStroke ? Ramipril: ? primary posite end point 22% ? Death from CVD: 26% ? MI: 20% ? Stroke 32% ? Death from any cause: 16% ?沙坦、硝苯地平、利尿藥 外科介入 ? 頸動(dòng)脈內(nèi)膜切除術(shù) ? 血管內(nèi)支架 教育患者： ?社區(qū)中發(fā)生 TIA者，或就診時(shí)已經(jīng)恢復(fù)良好的卒中者，應(yīng)該在起病 14天內(nèi)就診于有專家的神經(jīng)血管臨床機(jī)構(gòu)，接受評(píng)價(jià)和觀察。 ?不要等待！ 小卒中、卒中前兆、短暫性腦卒中
環(huán)評(píng)公示相關(guān)推薦
鄂ICP備17016276號(hào)-1